Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged UBS

E&Y Explains The New SEBI Delisting & Insider Trading Regulations



SEBI has carried out important amendments to the SEBI (Delisting of Equity Shares) Regulations, 2009 and has approved the Prohibition of Insider Trading Regulations, 2014. Ernst & Young has carried out an expert analysis of these regulations

Two New Stock Picks Of Daljeet Kohli You Have To Keep An Eye On



Daljeet Kohli has announced OnMobile Global and Exide Industries as his latest stock picks. Given his track record at finding winning stocks, we need to be on red alert

Six More Stocks Worth Buying After Q2FY15 Results: Amar Ambani IIFL



Amar Ambani of IIFL has recommended six more stocks which he claims have good upside left in them

Update On Stocks After Q2FY15 Results: IndiaNivesh



IndiaNivesh has provided an update on the status of the stocks in their coverage universe after the Q2FY15 results

UBS Model Portfolio Of Top Ten Stocks For up to 44% return



The ET has carried a report on UBS’ favourite sectors and stocks. UBS has shortlisted 10 stocks which it claims will deliver up to 44% returns in the next 12 months

Three More Stocks Worth Buying After Q2FY15 Results: Amar Ambani IIFL



Amar Ambani of IIFL has recommended three more stocks which he claim have good upside left in them

Nine Stocks Worth Buying After Q2FY15 Results: Amar Ambani IIFL



Amar Ambani of IIFL has recommended nine stocks which he claim have good upside left in them

Rahul Arora Talks About His Favourite Stocks



Rahul Arora, CEO of Nirmal Bang, has identified his favourite stocks

Should We Buy Vaibhav Global Ahead Of Its Q2FY15 results?



Vaibhav Global’s business model of retailing through home TV shopping business model is highly scalable with limited investment. It’s Q1FY15 results got impacted owing to a one-time affair. Q2FY15 is a seasonally weak quarter. However, the management’s assertion that things will be normal in Q3FY15 suggests that we need to look into the matter closely

Should We Buy Or Sell Ajanta Pharma Now?



Ajanta Pharma has been a great wealth-creator stock. It reported robust Q2FY15 results. However, have the valuations run up ahead of fundamentals and should we sell the stock?

← Older Entries Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 499 other subscribers

RSS Stocks Talk Forum

  • Bharat’s Swarna Kaal: Analysis of Emerging Stock Ideas
    Bharat’s Swarna Kaal: Analysis of Emerging Stock Ideas like Aimtron Electronics, AWFIS, Balu Forge, Can Fin Homes, Concord Control, Jana Small Finance Bank, Karnataka Bank, Knowledge Marine, Krystal Integrated, Megatherm Induction, Repco Home Finance etc Download research report
  • L&T Finance's Project Cyclops will hog the limelight. TP ₹200 (42%)
    L&T Finance's Project Cyclops, the AI-driven multi-dimensional underwriting engine, will hog the limelight. This next gen underwriting engine is aimed at higher approval rates & delivering higher RoA by way of operating leverage & rationalising credit cost. TP ₹200 (42%) Download research... L&T Finance's Project Cyclops will hog the limelight. TP ₹200 (42%)
  • Top Conviction Stock Ideas
    Equity Investment Strategy: Market Shifting Gears; Time to Build Long-Term Portfolio. Top Conviction Ideas from BFSI, Infra, Cement, Pharma & Hospitals, FMCG, Retail, Chemicals & Mid-caps, Metals & Mining, Power & Transmission, Automobiles, IT & Telecom Download research report
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!